5F-CUMYL-PEGACLONE
Chemical compound
From Wikipedia, the free encyclopedia
5F-CUMYL-PEGACLONE (5F-SGT-151, SGT-269) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug, first being identified in Germany in 2017. It acts as a potent full agonist of the CB1 receptor.[1][2] It appears to be more toxic than related compounds such as CUMYL-PEGACLONE, and has been linked to numerous serious adverse reactions, some fatal.[3]
Legal status
- CA: Schedule II
- DE: NpSG (Industrial and scientific use only)
- UK: Under Psychoactive Substances Act
| Legal status | |
|---|---|
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C25H27FN2O |
| Molar mass | 390.502 g·mol−1 |
| 3D model (JSmol) | |
| |
| |